Results of the JUPITER trial showed that people with low LDL
cholesterol but with a high C-reactive protein level who took the
statin rosuvastatin had a dramatic decrease in risk of serious
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.